The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD

Earlier biologic initiation is recommended for Crohn's disease but real-world evidence quantifying the impact of timing on hard clinical outcomes—surgery and disease progression—in a large prospective US cohort had not been established, limiting the strength of evidence for early intervention guidelines.

The TARGET-IBD registry was used to compare rates of CD surgery and disease progression across patients stratified by time from diagnosis to biologic initiation (<1 month, 1–24 months, 2–5 years), using multivariable probit and Cox proportional hazard models funded by AbbVie.

Establishing that later biologic initiation is associated with significantly higher rates of CD surgery and disease progression in real-world practice provides the evidence foundation for early intervention guidelines and reinforces the prescriber and payer case for AbbVie's advanced therapies in newly diagnosed CD.

Real-world early biologic initiation benefit evidence for Crohn's disease treat-to-target prescriber education, Surgery and disease progression reduction evidence supporting AbbVie CD portfolio label and payer strategy, Time-to-biologic benchmarking for early intervention guideline development in CD